Clinical use of phosphodiesterases-5 inhibitors in cardiopulmonary diseases: From experimental evidence to clinical application;Gli inibitori della fosfodiesterasi-5 nella patologia cardiopolmonare: Dai rilievi sperimentali all'applicazione clinica

Giornale Italiano di Cardiologia

Volumn 10, Issue 11-12, 2009, Pages 725-737

  Guazzi, Marco ^a   Vicenzi, Marco ^a   Samaja, Michele ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Heart failure; Pulmonary arterial hypertension

Indexed keywords

CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL;

APOPTOSIS; CORONARY ARTERY DISEASE; ENZYME INACTIVATION; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IDIOPATHIC DISEASE; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER;

ADMINISTRATION, ORAL; ANIMALS; CARBOLINES; CLINICAL TRIALS AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FOLLOW-UP STUDIES; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, ANIMAL; MYOCARDIAL REPERFUSION INJURY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TIME FACTORS; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 72949091311     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Jackson G, Gillies H, Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005; 59: 680-691 (Pubitemid 44192639)
2. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res MoI Biol 2001; 65: 1-52.
3. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414.
4. Waldkirch E, Uckert S, Yildirim H, et al. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries - immunohistochemical distribution and functional significance. World J Urol 2005; 23: 405-410 (Pubitemid 43124392)
5. 2+ release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. Am J Physiol Cell Physiol 2005; 288: C650-C658. (Pubitemid 40229494)
6. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003; 9: 1498-1505 (Pubitemid 38004777)
7. Singel DJ, Stamler JS. Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Annu Rev Physiol 2005; 67: 99-145.
8. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142
9. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 2000; 27: 313-319 (Pubitemid 30194171)
10. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 1958; 232: 1077-1091
11. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 2003; 160: 719-727 (Pubitemid 36298267)
12. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-280 (Pubitemid 41097665)
13. Day JP, Dow JA, Houslay MD, Davies SA. Cyclic nucleotide phosphodiesterases in Drosophila melanogaster. Biochem J. 2005; 388 (Pt 1): 333-342
14. Lin CS, Chow S, Lau A, Tu R, Lue TF. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001; 280: 693-699 (Pubitemid 32924485)
15. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702. Revisione estesa delle basi fisiopatologiche ed evidenza clinica circa I'impiego degli inibitori della fosfodiesterasi-5 in diverse patologie cardiovascolari.
16. Boyle CD, Xu R, Asberom T, et al. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. Bioorg Med Chem Lett 2005; 15: 2365-2369 (Pubitemid 40523101)
17. Sung BJ, Hwang KY, Jeon YH, et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003; 425: 98-102.
18. Corbin J, Francis S, Zoraghi R. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. Int J Impot Res 2006; 18: 251-257
19. Zoraghi R, Corbin JD, Francis SH. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 2006; 281: 5553-5558 (Pubitemid 43847651)
20. Wang H, Liu Y, Huai Q, et al. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 2006; 281: 21469-21479 (Pubitemid 44115485)
21. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol 2006; 70: 1822-1831 (Pubitemid 44776442)
22. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006; 316: 654-661
23. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5-9. (Pubitemid 40299987)
24. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
25. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng LJ, Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400-403 (Pubitemid 36999855)
26. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
27. Moncada I, Jara J, Subira D, Castano I, Hernandez C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 2004; 46: 357-361 (Pubitemid 39078571)
28. Corbin J, Rannels S, Neal D, et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747-752 (Pubitemid 37466145)
29. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626 (Pubitemid 30341530)
30. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112: 2642-2649 (Pubitemid 41532601)
31. Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-109 (Pubitemid 40095759)
32. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222 Studio sperimentale particolarmente rilevante per la dimostrazione che il sildenafil è in grado di inibire la risposta ipertrofica del ventricolo sinistra che si sviluppa in conseguenza di un sovraccarico pressorio.
33. Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005; 5: 10.
34. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am J Physiol 1986; 251 (6 Pt 2): H1306-H1315.
35. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during sustained ischemic episode. Circ Res 1990; 66: 913-931
36. Reimer KA, Murry CE, Jennings RB. Cardiac adaptation to ischemia. Ischemic preconditioning increases myocardial tolerance to subsequent ischemic episodes. Circulation 1990; 82: 2266-2268
37. Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990; 82 (3 Suppl): II2-II12.
38. Murry CE, Jennings RB, Reimer KA. New insights into potential mechanisms of ischemic preconditioning. Circulation 1991; 84: 442-445
39. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007; 150: 567-576 (Pubitemid 46355556)
40. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-1151
41. ATP channels in rabbits. Am J Physiol Heart Circ Physiol 2002; 283: H1263-H1269. (Pubitemid 34941065)
42. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003; 92: 595-597 (Pubitemid 36417692)
43. Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′- monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res 2002; 28: 213-219 (Pubitemid 36596885)
44. Das A, Ockaili R, Salloum F, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 2004; 286: H1455-H1460. (Pubitemid 38381155)
45. Kukreja RC, Ockaili R, Salloum F, et al. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 2004; 36: 165-173 (Pubitemid 38202344)
46. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005; 280: 12944-12955 (Pubitemid 40491117)
47. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005; 111: 742-746 (Pubitemid 40250634)
48. Kukreja RC, Salloum F, Das A, et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol 2005; 42: 219-232 (Pubitemid 40726325)
49. Fox KM, Thadani U, Ma PT, et al, for the CAESAR I (Clinical American and European Studies of Angina and Revascularization) Investigators. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; 24: 2206-2212
50. Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240
51. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097-1103 (Pubitemid 34970850)
52. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001; 15: 707-713 (Pubitemid 32975870)
53. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851 (Pubitemid 30681608)
54. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336-1339 (Pubitemid 41071142)
55. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 1998; 43: 163-168 (Pubitemid 28086352)
56. Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005; 171: 275-281
57. Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005; 60: 683-687 (Pubitemid 41129068)
58. Guilluy C, Sauzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005; 146: 1010-1018 (Pubitemid 41722174)
59. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-138 (Pubitemid 40361605)
60. Bianciardi P, Fantacci M, Caretti A, et al. Chronic in vivo hypoxia in various organs: hypoxia-inducible factor-1 alpha and apoptosis. Biochem Biophys Res Commun 2006; 342: 875-880 (Pubitemid 43320479)
61. Fantacci M, Bianciardi P, Caretti A, et al. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci USA 2006; 103: 17531-17536 (Pubitemid 44789003)
62. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107: 3230-3235 (Pubitemid 36793096)
63. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111: 1601-1610 (Pubitemid 40525159)
64. Wilkins MR, Aldashev A, Morrell NW. Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions. Lancet 2002; 359: 1539-1540 (Pubitemid 34621117)
65. Feenstra J, van Drie-Pierik RJ, Lacle CF, Stricker BH. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 957-958 (Pubitemid 28427282)
66. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86: 57F-61F.
67. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74. (Pubitemid 28286822)
68. Conti CR, Pepine O, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29C-34C.
69. Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651-652 (Pubitemid 32234500)
70. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331-1334 (Pubitemid 34606905)
71. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003; 57: 597-600. (Pubitemid 37185074)
72. Kloner RA. Erectile dysfunction in the cardiac patient. Compr Ther 2004; 30: 50-54
73. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004; 93: 147-153 (Pubitemid 38058721)
74. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C. (Pubitemid 29122753)
75. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003; 108: 239-244 (Pubitemid 36871309)
76. Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am J Med 2000; 109 (Suppl 9A): 13S-30S.
77. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92: 37M-46M.
78. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-28C. (Pubitemid 29122754)
79. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25-31. (Pubitemid 30466107)
80. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273-282
81. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368
82. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
83. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954 (Pubitemid 30131694)
84. Kharbanda RK, Peters M, Walton B, et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 2001; 103: 1624-1630 (Pubitemid 32246608)
85. Vlachopoulos C, Alexopoulos N, Panagiotakos D, O'Rourke MF, Stefanadis C. Cigar smoking has an acute detrimental effect on arterial stiffness. Am J Hypertens 2004; 17: 299-303. (Pubitemid 38446843)
86. Robinson SD, Ludlam CA, Boon NA, Newby DE. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2006; 92: 170-176
87. Attinà TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008; 26: 501-507
88. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C. (Pubitemid 29122752)
89. Ahn HS, Crim W, Pitts B, Sybertz EJ. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprotein Res 1992; 25: 271-288
90. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 2002; 86: 131-141 (Pubitemid 35284801)
91. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576-582 (Pubitemid 29097959)
92. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719-725 (Pubitemid 34250457)
93. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006-2012 (Pubitemid 35425369)
94. Simonneau G, Galiè N, Rubin U, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 5S-12S.
95. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102.
96. Cogan JD, Vnencak-Jones CL, Phillips JA 3rd, et al. Gross BM-PR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005; 7: 169-174
97. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90: 677-680 (Pubitemid 35264557)
98. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-1653 (Pubitemid 46218790)
99. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222 (Pubitemid 32848108)
100. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522 (Pubitemid 34252285)
101. Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002; 105: 244-250
102. Galiè N, Ghofrani HA, Torbicki A, et al, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hyperten- sion. N Engl J Med 2005; 353: 2148-57. Studio condotto in 278 pazienti con ipertensione polmonare sintomatica, in classe funzionale II/III, che hanno ricevuto sildenafil orale (20, 40, 80 mg 3 volte/die) per 12 settimane, o placebo. L'endpoint primario per la valutazione dell'efficacia della terapia è stato il test dei 6 min. Il sildenafil si è mostrato ben tollerato a tutte le dosi con effetto favorevole su emodinamica, tolleranza all'esercizio e classe funzionale.
103. Haynes J Jr, Kithas PA, Taylor AE, Strada SJ. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am J Physiol 1991; 261 (2 Pt 2): H487-H492.
104. Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003; 107: 234-237 (Pubitemid 36135217)
105. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-428 (Pubitemid 32678272)
106. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
107. Wharton J, Strange JW, Møller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-13.
108. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270 (Pubitemid 28389516)
109. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
110. Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 1995; 25: 1656-1664
111. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900. (Pubitemid 35283832)
112. Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and toler ability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55: 55-59 (Pubitemid 36582684)
113. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-9.
114. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496 (Pubitemid 39303954)
115. Ruiz MJ, Escribano P, Delgado JF, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant 2006; 25: 1353-1357 (Pubitemid 44692511)
116. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141 (Pubitemid 36459662)
117. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006; 114: 1807-1810 (Pubitemid 44673355)
118. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1-e5.
119. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120: 301-305
120. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15: 1747-1748
121. Al-Hesayen A, Floras JS, Parker JD. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006; 8: 864-8.
122. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000; 102: 3068-3073
123. Chua TP, Coats AJ. The lungs in chronic heart failure. Eur Heart J 1995; 16: 882-887
124. Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 2003; 124: 1090-1102 (Pubitemid 37123333)
125. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339-2348 Prima evidenza che la somministrazione acuta di sildenafil (50 mg) migliori la diffusione alveolo-capillare per il monossido di carbonio, consume di ossigeno di picco ed efficienza ventilatoria da sforzo in pazienti con ipertensione polmonare da disfunzione ventricolare sinistra di grado lieve-moderato.
126. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59-66. (Pubitemid 46058612)
127. Klodell CT Jr, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007; 83: 68-71.
128. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96: 1436-1440 (Pubitemid 41566628)
129. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48: 622-627
130. Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 2004; 76: 371-8.
131. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851 (Pubitemid 30681608)
132. Hryniewicz K, Dimayuga C, Hudaihed A, et al. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond)2005; 108: 331-338 (Pubitemid 40516996)
133. Chen Y, Traverse JH, Hou M, Li Y, Du R, Bache RJ. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H1513-H1520. (Pubitemid 36460761)
134. 2 partial pressure. Eur Heart J 2005; 26: 472-480 (Pubitemid 40314763)
135. 2. Eur Heart J 2000; 21: 154-161 (Pubitemid 30072630)
136. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-2144 Studio placebo-controllato che ha coinvolto 44 pazienti con insufficienza cardiaca cronica in condizioni stabili e trattati in maniera ottimale con terapia medica, randomizzati a 6 mesi di terapia con sildenafil (50 mg 3 volte/die) o placebo. L'inibizione della fosfodiesterasi-5 ha determinato un significative miglioramento della funzione endoteliale, della performance fisica massima e dell'efficienza ventilatoria. Lo studio evidenzia anche un miglioramento soggettivo in termini di qualità di vita e sintomi (sensazione dispnoica).
137. Benedict N, Seybert A, Mathier AM. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29: 2134-2153 (Pubitemid 350138566)
138. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding role in cardiovascular regulation. Circ Res 2007; 101: 1084-1095
139. Croom KF, Curran MP, Abman SH, et al. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 2008; 68: 383-397 (Pubitemid 351227349)